Modulation of mitochondrial protein kinase C isozymes: A new therapeutic frontier?

Tiffany Nguyen, Mourad Ogbi, Dehuang Guo, John A Johnson

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Alterations in protein kinase C (PKC) isozymes and mitochondrial functions such as oxidative phosphorylation (OXPHOS) and apoptosis have each been implicated in human diseases. However, relatively little is currently understood regarding the physiologic roles of individual PKC isozymes or their substrates for phosphorylation in mitochondria. Recent advances in mitochondrial localization of PKC isozymes and methods of PKC isozyme-selective inhibition have made possible a more focused pursuit of these relationships. Studies of PKC isozyme involvement in areas such as mitochondrial ROS production, antioxidant defense, energetics, and apoptosis are now possible and hold the potential to provide promising pharmaceuticals for therapies against cardiovascular, diabetic, cancer and other diseases. The purpose of this review is to present the current state of knowledge illustrating a link between PKC isozymes, mitochondria and human disease. Novel strategies for PKC isozyme-selective inhibition will also be discussed with an emphasis on the rational targeting of mitochondrial PKC isozymes in research and clinical settings.

Original languageEnglish (US)
Pages (from-to)143-159
Number of pages17
JournalCurrent Enzyme Inhibition
Volume3
Issue number2
DOIs
StatePublished - May 1 2007

Fingerprint

Mitochondrial Proteins
Protein Kinase C
Isoenzymes
Modulation
Mitochondria
Therapeutics
Apoptosis
Phosphorylation
Oxidative Phosphorylation
Antioxidants
Substrates
Research
Pharmaceutical Preparations

Keywords

  • Antisense
  • Apoptosis
  • Disease
  • Energetics
  • Mitochondria
  • Protein kinase C isozyme-selective inhibition
  • Pseudosubstrate
  • ROS
  • Translocation inhibitors

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Drug Discovery

Cite this

Modulation of mitochondrial protein kinase C isozymes : A new therapeutic frontier? / Nguyen, Tiffany; Ogbi, Mourad; Guo, Dehuang; Johnson, John A.

In: Current Enzyme Inhibition, Vol. 3, No. 2, 01.05.2007, p. 143-159.

Research output: Contribution to journalReview article

Nguyen, Tiffany ; Ogbi, Mourad ; Guo, Dehuang ; Johnson, John A. / Modulation of mitochondrial protein kinase C isozymes : A new therapeutic frontier?. In: Current Enzyme Inhibition. 2007 ; Vol. 3, No. 2. pp. 143-159.
@article{58a110bbe5e14244bf09581e6f6db8b4,
title = "Modulation of mitochondrial protein kinase C isozymes: A new therapeutic frontier?",
abstract = "Alterations in protein kinase C (PKC) isozymes and mitochondrial functions such as oxidative phosphorylation (OXPHOS) and apoptosis have each been implicated in human diseases. However, relatively little is currently understood regarding the physiologic roles of individual PKC isozymes or their substrates for phosphorylation in mitochondria. Recent advances in mitochondrial localization of PKC isozymes and methods of PKC isozyme-selective inhibition have made possible a more focused pursuit of these relationships. Studies of PKC isozyme involvement in areas such as mitochondrial ROS production, antioxidant defense, energetics, and apoptosis are now possible and hold the potential to provide promising pharmaceuticals for therapies against cardiovascular, diabetic, cancer and other diseases. The purpose of this review is to present the current state of knowledge illustrating a link between PKC isozymes, mitochondria and human disease. Novel strategies for PKC isozyme-selective inhibition will also be discussed with an emphasis on the rational targeting of mitochondrial PKC isozymes in research and clinical settings.",
keywords = "Antisense, Apoptosis, Disease, Energetics, Mitochondria, Protein kinase C isozyme-selective inhibition, Pseudosubstrate, ROS, Translocation inhibitors",
author = "Tiffany Nguyen and Mourad Ogbi and Dehuang Guo and Johnson, {John A}",
year = "2007",
month = "5",
day = "1",
doi = "10.2174/157340807780598396",
language = "English (US)",
volume = "3",
pages = "143--159",
journal = "Current Enzyme Inhibition",
issn = "1573-4080",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Modulation of mitochondrial protein kinase C isozymes

T2 - A new therapeutic frontier?

AU - Nguyen, Tiffany

AU - Ogbi, Mourad

AU - Guo, Dehuang

AU - Johnson, John A

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Alterations in protein kinase C (PKC) isozymes and mitochondrial functions such as oxidative phosphorylation (OXPHOS) and apoptosis have each been implicated in human diseases. However, relatively little is currently understood regarding the physiologic roles of individual PKC isozymes or their substrates for phosphorylation in mitochondria. Recent advances in mitochondrial localization of PKC isozymes and methods of PKC isozyme-selective inhibition have made possible a more focused pursuit of these relationships. Studies of PKC isozyme involvement in areas such as mitochondrial ROS production, antioxidant defense, energetics, and apoptosis are now possible and hold the potential to provide promising pharmaceuticals for therapies against cardiovascular, diabetic, cancer and other diseases. The purpose of this review is to present the current state of knowledge illustrating a link between PKC isozymes, mitochondria and human disease. Novel strategies for PKC isozyme-selective inhibition will also be discussed with an emphasis on the rational targeting of mitochondrial PKC isozymes in research and clinical settings.

AB - Alterations in protein kinase C (PKC) isozymes and mitochondrial functions such as oxidative phosphorylation (OXPHOS) and apoptosis have each been implicated in human diseases. However, relatively little is currently understood regarding the physiologic roles of individual PKC isozymes or their substrates for phosphorylation in mitochondria. Recent advances in mitochondrial localization of PKC isozymes and methods of PKC isozyme-selective inhibition have made possible a more focused pursuit of these relationships. Studies of PKC isozyme involvement in areas such as mitochondrial ROS production, antioxidant defense, energetics, and apoptosis are now possible and hold the potential to provide promising pharmaceuticals for therapies against cardiovascular, diabetic, cancer and other diseases. The purpose of this review is to present the current state of knowledge illustrating a link between PKC isozymes, mitochondria and human disease. Novel strategies for PKC isozyme-selective inhibition will also be discussed with an emphasis on the rational targeting of mitochondrial PKC isozymes in research and clinical settings.

KW - Antisense

KW - Apoptosis

KW - Disease

KW - Energetics

KW - Mitochondria

KW - Protein kinase C isozyme-selective inhibition

KW - Pseudosubstrate

KW - ROS

KW - Translocation inhibitors

UR - http://www.scopus.com/inward/record.url?scp=34248656510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248656510&partnerID=8YFLogxK

U2 - 10.2174/157340807780598396

DO - 10.2174/157340807780598396

M3 - Review article

AN - SCOPUS:34248656510

VL - 3

SP - 143

EP - 159

JO - Current Enzyme Inhibition

JF - Current Enzyme Inhibition

SN - 1573-4080

IS - 2

ER -